nodes	percent_of_prediction	percent_of_DWPC	metapath
Crizotinib—EPHA2—pulmonary artery—chronic obstructive pulmonary disease	0.00929	0.0279	CbGeAlD
Crizotinib—ROS1—respiratory system—chronic obstructive pulmonary disease	0.00797	0.0239	CbGeAlD
Crizotinib—RPS6KB1—leg—chronic obstructive pulmonary disease	0.00678	0.0204	CbGeAlD
Crizotinib—ROS1—lung—chronic obstructive pulmonary disease	0.00423	0.0127	CbGeAlD
Crizotinib—NEK9—respiratory system—chronic obstructive pulmonary disease	0.00396	0.0119	CbGeAlD
Crizotinib—Electrocardiogram QT prolonged—Arformoterol—chronic obstructive pulmonary disease	0.00366	0.0147	CcSEcCtD
Crizotinib—PRKD1—respiratory system—chronic obstructive pulmonary disease	0.00361	0.0108	CbGeAlD
Crizotinib—NEK9—connective tissue—chronic obstructive pulmonary disease	0.00349	0.0105	CbGeAlD
Crizotinib—TXK—respiratory system—chronic obstructive pulmonary disease	0.00321	0.00963	CbGeAlD
Crizotinib—SIK2—connective tissue—chronic obstructive pulmonary disease	0.00313	0.00941	CbGeAlD
Crizotinib—MET—respiratory system—chronic obstructive pulmonary disease	0.003	0.00901	CbGeAlD
Crizotinib—Abscess—Formoterol—chronic obstructive pulmonary disease	0.00297	0.0119	CcSEcCtD
Crizotinib—Abscess—Arformoterol—chronic obstructive pulmonary disease	0.00297	0.0119	CcSEcCtD
Crizotinib—PRKD1—smooth muscle tissue—chronic obstructive pulmonary disease	0.00291	0.00873	CbGeAlD
Crizotinib—CDK7—respiratory system—chronic obstructive pulmonary disease	0.0029	0.00872	CbGeAlD
Crizotinib—MAPK7—connective tissue—chronic obstructive pulmonary disease	0.00282	0.00848	CbGeAlD
Crizotinib—DSTYK—bronchus—chronic obstructive pulmonary disease	0.00279	0.00837	CbGeAlD
Crizotinib—MET—connective tissue—chronic obstructive pulmonary disease	0.00264	0.00793	CbGeAlD
Crizotinib—Weight decreased—Roflumilast—chronic obstructive pulmonary disease	0.00263	0.0106	CcSEcCtD
Crizotinib—PLK4—respiratory system—chronic obstructive pulmonary disease	0.00261	0.00785	CbGeAlD
Crizotinib—Pneumonia—Roflumilast—chronic obstructive pulmonary disease	0.0026	0.0105	CcSEcCtD
Crizotinib—Infestation NOS—Roflumilast—chronic obstructive pulmonary disease	0.00259	0.0104	CcSEcCtD
Crizotinib—Infestation—Roflumilast—chronic obstructive pulmonary disease	0.00259	0.0104	CcSEcCtD
Crizotinib—CDK7—connective tissue—chronic obstructive pulmonary disease	0.00256	0.00767	CbGeAlD
Crizotinib—MET—bronchus—chronic obstructive pulmonary disease	0.00247	0.00742	CbGeAlD
Crizotinib—ALK—respiratory system—chronic obstructive pulmonary disease	0.00246	0.00737	CbGeAlD
Crizotinib—Hepatobiliary disease—Roflumilast—chronic obstructive pulmonary disease	0.00245	0.00984	CcSEcCtD
Crizotinib—MAP3K19—respiratory system—chronic obstructive pulmonary disease	0.00241	0.00722	CbGeAlD
Crizotinib—IGF1R—respiratory system—chronic obstructive pulmonary disease	0.00236	0.00708	CbGeAlD
Crizotinib—JAK3—connective tissue—chronic obstructive pulmonary disease	0.00233	0.007	CbGeAlD
Crizotinib—TIE1—respiratory system—chronic obstructive pulmonary disease	0.00229	0.00689	CbGeAlD
Crizotinib—STK4—connective tissue—chronic obstructive pulmonary disease	0.00229	0.00687	CbGeAlD
Crizotinib—TYRO3—connective tissue—chronic obstructive pulmonary disease	0.00216	0.00649	CbGeAlD
Crizotinib—ALK—connective tissue—chronic obstructive pulmonary disease	0.00216	0.00649	CbGeAlD
Crizotinib—Neuropathy—Montelukast—chronic obstructive pulmonary disease	0.00216	0.00868	CcSEcCtD
Crizotinib—Cardiac disorder—Roflumilast—chronic obstructive pulmonary disease	0.00216	0.00867	CcSEcCtD
Crizotinib—LYN—connective tissue—chronic obstructive pulmonary disease	0.00215	0.00646	CbGeAlD
Crizotinib—LIMK2—respiratory system—chronic obstructive pulmonary disease	0.00211	0.00634	CbGeAlD
Crizotinib—NEK9—lung—chronic obstructive pulmonary disease	0.0021	0.00632	CbGeAlD
Crizotinib—Mediastinal disorder—Roflumilast—chronic obstructive pulmonary disease	0.00209	0.00842	CcSEcCtD
Crizotinib—FLT3—respiratory system—chronic obstructive pulmonary disease	0.00209	0.00627	CbGeAlD
Crizotinib—ACVR1—respiratory system—chronic obstructive pulmonary disease	0.00209	0.00627	CbGeAlD
Crizotinib—IGF1R—connective tissue—chronic obstructive pulmonary disease	0.00208	0.00624	CbGeAlD
Crizotinib—Hypokalaemia—Aminophylline—chronic obstructive pulmonary disease	0.00204	0.00819	CcSEcCtD
Crizotinib—Malnutrition—Roflumilast—chronic obstructive pulmonary disease	0.00202	0.00813	CcSEcCtD
Crizotinib—FER—bronchus—chronic obstructive pulmonary disease	0.00202	0.00607	CbGeAlD
Crizotinib—TNK1—bronchus—chronic obstructive pulmonary disease	0.002	0.00601	CbGeAlD
Crizotinib—Dysgeusia—Roflumilast—chronic obstructive pulmonary disease	0.00198	0.00796	CcSEcCtD
Crizotinib—MAP4K1—bronchus—chronic obstructive pulmonary disease	0.00198	0.00595	CbGeAlD
Crizotinib—BMPR1B—bronchus—chronic obstructive pulmonary disease	0.00198	0.00595	CbGeAlD
Crizotinib—TESK1—connective tissue—chronic obstructive pulmonary disease	0.00195	0.00586	CbGeAlD
Crizotinib—DCLK1—trachea—chronic obstructive pulmonary disease	0.00194	0.00584	CbGeAlD
Crizotinib—PRKD1—lung—chronic obstructive pulmonary disease	0.00192	0.00576	CbGeAlD
Crizotinib—PTK2B—respiratory system—chronic obstructive pulmonary disease	0.0019	0.00571	CbGeAlD
Crizotinib—IGF1R—smooth muscle tissue—chronic obstructive pulmonary disease	0.0019	0.0057	CbGeAlD
Crizotinib—STK3—bronchus—chronic obstructive pulmonary disease	0.00189	0.00567	CbGeAlD
Crizotinib—TIE1—smooth muscle tissue—chronic obstructive pulmonary disease	0.00185	0.00555	CbGeAlD
Crizotinib—PRKD3—lung—chronic obstructive pulmonary disease	0.00184	0.00553	CbGeAlD
Crizotinib—ACVR1—connective tissue—chronic obstructive pulmonary disease	0.00184	0.00552	CbGeAlD
Crizotinib—FLT3—connective tissue—chronic obstructive pulmonary disease	0.00184	0.00552	CbGeAlD
Crizotinib—TESK1—bronchus—chronic obstructive pulmonary disease	0.00183	0.00548	CbGeAlD
Crizotinib—FER—trachea—chronic obstructive pulmonary disease	0.00181	0.00545	CbGeAlD
Crizotinib—Lymphopenia—Prednisone—chronic obstructive pulmonary disease	0.00181	0.00726	CcSEcCtD
Crizotinib—DSTYK—lung—chronic obstructive pulmonary disease	0.0018	0.0054	CbGeAlD
Crizotinib—TNK1—trachea—chronic obstructive pulmonary disease	0.0018	0.00539	CbGeAlD
Crizotinib—LTK—lung—chronic obstructive pulmonary disease	0.00176	0.00528	CbGeAlD
Crizotinib—CASK—lung—chronic obstructive pulmonary disease	0.00176	0.00528	CbGeAlD
Crizotinib—TBK1—respiratory system—chronic obstructive pulmonary disease	0.00175	0.00526	CbGeAlD
Crizotinib—PTK2—respiratory system—chronic obstructive pulmonary disease	0.00175	0.00526	CbGeAlD
Crizotinib—TYK2—respiratory system—chronic obstructive pulmonary disease	0.00174	0.00522	CbGeAlD
Crizotinib—LIMK2—bronchus—chronic obstructive pulmonary disease	0.00174	0.00522	CbGeAlD
Crizotinib—BMP2K—connective tissue—chronic obstructive pulmonary disease	0.00173	0.0052	CbGeAlD
Crizotinib—MAP3K12—bronchus—chronic obstructive pulmonary disease	0.00172	0.00516	CbGeAlD
Crizotinib—ACVR1—bronchus—chronic obstructive pulmonary disease	0.00172	0.00516	CbGeAlD
Crizotinib—Unspecified disorder of skin and subcutaneous tissue—Roflumilast—chronic obstructive pulmonary disease	0.00171	0.00687	CcSEcCtD
Crizotinib—MAPK7—lung—chronic obstructive pulmonary disease	0.0017	0.00511	CbGeAlD
Crizotinib—TXK—lung—chronic obstructive pulmonary disease	0.0017	0.00511	CbGeAlD
Crizotinib—Upper respiratory tract infection—Tiotropium—chronic obstructive pulmonary disease	0.0017	0.00682	CcSEcCtD
Crizotinib—FES—lung—chronic obstructive pulmonary disease	0.00169	0.00506	CbGeAlD
Crizotinib—RPS6KB1—respiratory system—chronic obstructive pulmonary disease	0.00168	0.00506	CbGeAlD
Crizotinib—FGR—respiratory system—chronic obstructive pulmonary disease	0.00167	0.00503	CbGeAlD
Crizotinib—PTK2B—connective tissue—chronic obstructive pulmonary disease	0.00167	0.00503	CbGeAlD
Crizotinib—AXL—respiratory system—chronic obstructive pulmonary disease	0.00167	0.00501	CbGeAlD
Crizotinib—RIPK2—connective tissue—chronic obstructive pulmonary disease	0.00166	0.00499	CbGeAlD
Crizotinib—Infection—Roflumilast—chronic obstructive pulmonary disease	0.00164	0.00659	CcSEcCtD
Crizotinib—TESK1—trachea—chronic obstructive pulmonary disease	0.00164	0.00492	CbGeAlD
Crizotinib—BMP2K—bronchus—chronic obstructive pulmonary disease	0.00162	0.00487	CbGeAlD
Crizotinib—Nervous system disorder—Roflumilast—chronic obstructive pulmonary disease	0.00162	0.00651	CcSEcCtD
Crizotinib—Abscess—Prednisolone—chronic obstructive pulmonary disease	0.00161	0.00646	CcSEcCtD
Crizotinib—Skin disorder—Roflumilast—chronic obstructive pulmonary disease	0.0016	0.00645	CcSEcCtD
Crizotinib—MET—lung—chronic obstructive pulmonary disease	0.00159	0.00479	CbGeAlD
Crizotinib—EPHB4—respiratory system—chronic obstructive pulmonary disease	0.00159	0.00479	CbGeAlD
Crizotinib—JAK2—respiratory system—chronic obstructive pulmonary disease	0.00158	0.00475	CbGeAlD
Crizotinib—MAP3K2—connective tissue—chronic obstructive pulmonary disease	0.00157	0.00473	CbGeAlD
Crizotinib—EPHA2—respiratory system—chronic obstructive pulmonary disease	0.00156	0.00469	CbGeAlD
Crizotinib—LIMK2—trachea—chronic obstructive pulmonary disease	0.00156	0.00468	CbGeAlD
Crizotinib—NUAK2—trachea—chronic obstructive pulmonary disease	0.00155	0.00467	CbGeAlD
Crizotinib—RIPK2—bronchus—chronic obstructive pulmonary disease	0.00155	0.00466	CbGeAlD
Crizotinib—Hypokalaemia—Arformoterol—chronic obstructive pulmonary disease	0.00155	0.00624	CcSEcCtD
Crizotinib—Hypokalaemia—Formoterol—chronic obstructive pulmonary disease	0.00155	0.00624	CcSEcCtD
Crizotinib—ACVR1—trachea—chronic obstructive pulmonary disease	0.00154	0.00463	CbGeAlD
Crizotinib—CDK7—lung—chronic obstructive pulmonary disease	0.00154	0.00463	CbGeAlD
Crizotinib—PTK2—connective tissue—chronic obstructive pulmonary disease	0.00154	0.00463	CbGeAlD
Crizotinib—Febrile neutropenia—Prednisone—chronic obstructive pulmonary disease	0.00154	0.00618	CcSEcCtD
Crizotinib—PTK2B—smooth muscle tissue—chronic obstructive pulmonary disease	0.00153	0.0046	CbGeAlD
Crizotinib—TYK2—connective tissue—chronic obstructive pulmonary disease	0.00153	0.0046	CbGeAlD
Crizotinib—TAOK2—lung—chronic obstructive pulmonary disease	0.00153	0.00459	CbGeAlD
Crizotinib—TEK—respiratory system—chronic obstructive pulmonary disease	0.00153	0.00458	CbGeAlD
Crizotinib—Aspartate aminotransferase increased—Montelukast—chronic obstructive pulmonary disease	0.0015	0.00604	CcSEcCtD
Crizotinib—EPHA4—bronchus—chronic obstructive pulmonary disease	0.0015	0.00451	CbGeAlD
Crizotinib—RPS6KB1—connective tissue—chronic obstructive pulmonary disease	0.00148	0.00445	CbGeAlD
Crizotinib—ACVR1B—lung—chronic obstructive pulmonary disease	0.00147	0.00442	CbGeAlD
Crizotinib—EPHA3—lung—chronic obstructive pulmonary disease	0.00147	0.00442	CbGeAlD
Crizotinib—Alanine aminotransferase increased—Montelukast—chronic obstructive pulmonary disease	0.00147	0.00592	CcSEcCtD
Crizotinib—AXL—connective tissue—chronic obstructive pulmonary disease	0.00147	0.00441	CbGeAlD
Crizotinib—Hypokalaemia—Salbutamol—chronic obstructive pulmonary disease	0.00147	0.00589	CcSEcCtD
Crizotinib—Dyspepsia—Roflumilast—chronic obstructive pulmonary disease	0.00145	0.00584	CcSEcCtD
Crizotinib—Urinary tract disorder—Tiotropium—chronic obstructive pulmonary disease	0.00144	0.0058	CcSEcCtD
Crizotinib—TBK1—bronchus—chronic obstructive pulmonary disease	0.00144	0.00433	CbGeAlD
Crizotinib—PTK2—bronchus—chronic obstructive pulmonary disease	0.00144	0.00433	CbGeAlD
Crizotinib—Oedema peripheral—Tiotropium—chronic obstructive pulmonary disease	0.00144	0.00579	CcSEcCtD
Crizotinib—Decreased appetite—Roflumilast—chronic obstructive pulmonary disease	0.00144	0.00577	CcSEcCtD
Crizotinib—Urethral disorder—Tiotropium—chronic obstructive pulmonary disease	0.00143	0.00576	CcSEcCtD
Crizotinib—TYK2—bronchus—chronic obstructive pulmonary disease	0.00143	0.0043	CbGeAlD
Crizotinib—Gastrointestinal disorder—Roflumilast—chronic obstructive pulmonary disease	0.00143	0.00573	CcSEcCtD
Crizotinib—Fatigue—Roflumilast—chronic obstructive pulmonary disease	0.00142	0.00572	CcSEcCtD
Crizotinib—IRAK1—bronchus—chronic obstructive pulmonary disease	0.00141	0.00424	CbGeAlD
Crizotinib—Constipation—Roflumilast—chronic obstructive pulmonary disease	0.00141	0.00567	CcSEcCtD
Crizotinib—PTK2—smooth muscle tissue—chronic obstructive pulmonary disease	0.00141	0.00423	CbGeAlD
Crizotinib—Visual impairment—Tiotropium—chronic obstructive pulmonary disease	0.00141	0.00566	CcSEcCtD
Crizotinib—YES1—respiratory system—chronic obstructive pulmonary disease	0.00141	0.00423	CbGeAlD
Crizotinib—JAK3—lung—chronic obstructive pulmonary disease	0.00141	0.00422	CbGeAlD
Crizotinib—EPHB4—connective tissue—chronic obstructive pulmonary disease	0.0014	0.00421	CbGeAlD
Crizotinib—TYK2—smooth muscle tissue—chronic obstructive pulmonary disease	0.0014	0.00421	CbGeAlD
Crizotinib—DCLK1—lung—chronic obstructive pulmonary disease	0.0014	0.00419	CbGeAlD
Crizotinib—STK10—respiratory system—chronic obstructive pulmonary disease	0.0014	0.00419	CbGeAlD
Crizotinib—RIPK2—trachea—chronic obstructive pulmonary disease	0.00139	0.00419	CbGeAlD
Crizotinib—JAK2—connective tissue—chronic obstructive pulmonary disease	0.00139	0.00418	CbGeAlD
Crizotinib—TAOK3—respiratory system—chronic obstructive pulmonary disease	0.00139	0.00418	CbGeAlD
Crizotinib—PLK4—lung—chronic obstructive pulmonary disease	0.00139	0.00417	CbGeAlD
Crizotinib—RPS6KB1—bronchus—chronic obstructive pulmonary disease	0.00139	0.00416	CbGeAlD
Crizotinib—Arrhythmia—Aminophylline—chronic obstructive pulmonary disease	0.00138	0.00556	CcSEcCtD
Crizotinib—IRAK1—smooth muscle tissue—chronic obstructive pulmonary disease	0.00138	0.00415	CbGeAlD
Crizotinib—STK4—lung—chronic obstructive pulmonary disease	0.00138	0.00414	CbGeAlD
Crizotinib—LCK—bronchus—chronic obstructive pulmonary disease	0.00138	0.00414	CbGeAlD
Crizotinib—Upper respiratory tract infection—Arformoterol—chronic obstructive pulmonary disease	0.00137	0.0055	CcSEcCtD
Crizotinib—Upper respiratory tract infection—Formoterol—chronic obstructive pulmonary disease	0.00137	0.0055	CcSEcCtD
Crizotinib—Eye disorder—Tiotropium—chronic obstructive pulmonary disease	0.00137	0.00549	CcSEcCtD
Crizotinib—RPS6KB1—smooth muscle tissue—chronic obstructive pulmonary disease	0.00136	0.00407	CbGeAlD
Crizotinib—SRC—respiratory system—chronic obstructive pulmonary disease	0.00135	0.00407	CbGeAlD
Crizotinib—EPHA4—trachea—chronic obstructive pulmonary disease	0.00135	0.00405	CbGeAlD
Crizotinib—AXL—smooth muscle tissue—chronic obstructive pulmonary disease	0.00134	0.00403	CbGeAlD
Crizotinib—TEK—connective tissue—chronic obstructive pulmonary disease	0.00134	0.00403	CbGeAlD
Crizotinib—Upper respiratory tract infection—Montelukast—chronic obstructive pulmonary disease	0.00134	0.00539	CcSEcCtD
Crizotinib—SLK—bronchus—chronic obstructive pulmonary disease	0.00132	0.00397	CbGeAlD
Crizotinib—Mediastinal disorder—Tiotropium—chronic obstructive pulmonary disease	0.00132	0.00529	CcSEcCtD
Crizotinib—EPHB4—bronchus—chronic obstructive pulmonary disease	0.00131	0.00394	CbGeAlD
Crizotinib—Arrhythmia—Tiotropium—chronic obstructive pulmonary disease	0.00131	0.00525	CcSEcCtD
Crizotinib—FER—lung—chronic obstructive pulmonary disease	0.0013	0.00392	CbGeAlD
Crizotinib—ALK—lung—chronic obstructive pulmonary disease	0.0013	0.00392	CbGeAlD
Crizotinib—JAK2—bronchus—chronic obstructive pulmonary disease	0.0013	0.00391	CbGeAlD
Crizotinib—Pneumonia—Montelukast—chronic obstructive pulmonary disease	0.00129	0.0052	CcSEcCtD
Crizotinib—TBK1—trachea—chronic obstructive pulmonary disease	0.00129	0.00389	CbGeAlD
Crizotinib—PTK2—trachea—chronic obstructive pulmonary disease	0.00129	0.00389	CbGeAlD
Crizotinib—Upper respiratory tract infection—Salbutamol—chronic obstructive pulmonary disease	0.00129	0.0052	CcSEcCtD
Crizotinib—TNK1—lung—chronic obstructive pulmonary disease	0.00129	0.00388	CbGeAlD
Crizotinib—Infestation NOS—Montelukast—chronic obstructive pulmonary disease	0.00129	0.00517	CcSEcCtD
Crizotinib—Infestation—Montelukast—chronic obstructive pulmonary disease	0.00129	0.00517	CcSEcCtD
Crizotinib—EPHA2—bronchus—chronic obstructive pulmonary disease	0.00129	0.00386	CbGeAlD
Crizotinib—TYK2—trachea—chronic obstructive pulmonary disease	0.00129	0.00386	CbGeAlD
Crizotinib—EPHB4—smooth muscle tissue—chronic obstructive pulmonary disease	0.00128	0.00385	CbGeAlD
Crizotinib—MAP3K19—lung—chronic obstructive pulmonary disease	0.00128	0.00384	CbGeAlD
Crizotinib—MAP4K1—lung—chronic obstructive pulmonary disease	0.00128	0.00384	CbGeAlD
Crizotinib—BMPR1B—lung—chronic obstructive pulmonary disease	0.00128	0.00384	CbGeAlD
Crizotinib—JAK2—smooth muscle tissue—chronic obstructive pulmonary disease	0.00127	0.00383	CbGeAlD
Crizotinib—Malnutrition—Tiotropium—chronic obstructive pulmonary disease	0.00127	0.00511	CcSEcCtD
Crizotinib—Neuropathy peripheral—Montelukast—chronic obstructive pulmonary disease	0.00126	0.00507	CcSEcCtD
Crizotinib—MAP3K3—bronchus—chronic obstructive pulmonary disease	0.00126	0.00377	CbGeAlD
Crizotinib—MAP4K5—bronchus—chronic obstructive pulmonary disease	0.00126	0.00377	CbGeAlD
Crizotinib—TEK—bronchus—chronic obstructive pulmonary disease	0.00126	0.00377	CbGeAlD
Crizotinib—IGF1R—lung—chronic obstructive pulmonary disease	0.00125	0.00376	CbGeAlD
Crizotinib—TNK2—lung—chronic obstructive pulmonary disease	0.00125	0.00376	CbGeAlD
Crizotinib—RPS6KB1—trachea—chronic obstructive pulmonary disease	0.00124	0.00374	CbGeAlD
Crizotinib—YES1—connective tissue—chronic obstructive pulmonary disease	0.00124	0.00372	CbGeAlD
Crizotinib—LCK—trachea—chronic obstructive pulmonary disease	0.00124	0.00372	CbGeAlD
Crizotinib—MAP4K2—lung—chronic obstructive pulmonary disease	0.00124	0.00371	CbGeAlD
Crizotinib—AXL—trachea—chronic obstructive pulmonary disease	0.00123	0.0037	CbGeAlD
Crizotinib—TEK—smooth muscle tissue—chronic obstructive pulmonary disease	0.00123	0.00369	CbGeAlD
Crizotinib—MAP4K5—smooth muscle tissue—chronic obstructive pulmonary disease	0.00123	0.00369	CbGeAlD
Crizotinib—TAOK3—connective tissue—chronic obstructive pulmonary disease	0.00122	0.00368	CbGeAlD
Crizotinib—STK3—lung—chronic obstructive pulmonary disease	0.00122	0.00366	CbGeAlD
Crizotinib—TIE1—lung—chronic obstructive pulmonary disease	0.00122	0.00366	CbGeAlD
Crizotinib—Hepatobiliary disease—Montelukast—chronic obstructive pulmonary disease	0.00122	0.00489	CcSEcCtD
Crizotinib—CSF1R—respiratory system—chronic obstructive pulmonary disease	0.00122	0.00365	CbGeAlD
Crizotinib—Neuropathy peripheral—Salbutamol—chronic obstructive pulmonary disease	0.00122	0.00489	CcSEcCtD
Crizotinib—Fluid retention—Prednisolone—chronic obstructive pulmonary disease	0.00121	0.00485	CcSEcCtD
Crizotinib—EPHB6—bronchus—chronic obstructive pulmonary disease	0.0012	0.0036	CbGeAlD
Crizotinib—Vision blurred—Tiotropium—chronic obstructive pulmonary disease	0.0012	0.00482	CcSEcCtD
Crizotinib—Neuropathy—Prednisolone—chronic obstructive pulmonary disease	0.00119	0.0048	CcSEcCtD
Crizotinib—SRC—connective tissue—chronic obstructive pulmonary disease	0.00119	0.00358	CbGeAlD
Crizotinib—AURKA—lung—chronic obstructive pulmonary disease	0.00119	0.00357	CbGeAlD
Crizotinib—SLK—trachea—chronic obstructive pulmonary disease	0.00119	0.00356	CbGeAlD
Crizotinib—Asthenia—Roflumilast—chronic obstructive pulmonary disease	0.00118	0.00476	CcSEcCtD
Crizotinib—TESK1—lung—chronic obstructive pulmonary disease	0.00118	0.00354	CbGeAlD
Crizotinib—EPHB4—trachea—chronic obstructive pulmonary disease	0.00118	0.00354	CbGeAlD
Crizotinib—JAK2—trachea—chronic obstructive pulmonary disease	0.00117	0.00351	CbGeAlD
Crizotinib—Abscess—Prednisone—chronic obstructive pulmonary disease	0.00117	0.0047	CcSEcCtD
Crizotinib—Urinary tract disorder—Formoterol—chronic obstructive pulmonary disease	0.00116	0.00468	CcSEcCtD
Crizotinib—Urinary tract disorder—Arformoterol—chronic obstructive pulmonary disease	0.00116	0.00468	CcSEcCtD
Crizotinib—Oedema peripheral—Arformoterol—chronic obstructive pulmonary disease	0.00116	0.00467	CcSEcCtD
Crizotinib—Oedema peripheral—Formoterol—chronic obstructive pulmonary disease	0.00116	0.00467	CcSEcCtD
Crizotinib—YES1—bronchus—chronic obstructive pulmonary disease	0.00116	0.00348	CbGeAlD
Crizotinib—Urethral disorder—Formoterol—chronic obstructive pulmonary disease	0.00116	0.00465	CcSEcCtD
Crizotinib—Urethral disorder—Arformoterol—chronic obstructive pulmonary disease	0.00116	0.00465	CcSEcCtD
Crizotinib—EPHA2—trachea—chronic obstructive pulmonary disease	0.00116	0.00347	CbGeAlD
Crizotinib—Hypoaesthesia—Montelukast—chronic obstructive pulmonary disease	0.00115	0.00462	CcSEcCtD
Crizotinib—STK10—bronchus—chronic obstructive pulmonary disease	0.00115	0.00345	CbGeAlD
Crizotinib—MERTK—lung—chronic obstructive pulmonary disease	0.00115	0.00344	CbGeAlD
Crizotinib—TAOK3—bronchus—chronic obstructive pulmonary disease	0.00114	0.00344	CbGeAlD
Crizotinib—Syncope—Tiotropium—chronic obstructive pulmonary disease	0.00114	0.00459	CcSEcCtD
Crizotinib—Urinary tract disorder—Montelukast—chronic obstructive pulmonary disease	0.00114	0.00459	CcSEcCtD
Crizotinib—Visual impairment—Formoterol—chronic obstructive pulmonary disease	0.00114	0.00457	CcSEcCtD
Crizotinib—Visual impairment—Arformoterol—chronic obstructive pulmonary disease	0.00114	0.00457	CcSEcCtD
Crizotinib—YES1—smooth muscle tissue—chronic obstructive pulmonary disease	0.00113	0.00341	CbGeAlD
Crizotinib—Urethral disorder—Montelukast—chronic obstructive pulmonary disease	0.00113	0.00455	CcSEcCtD
Crizotinib—Diarrhoea—Roflumilast—chronic obstructive pulmonary disease	0.00113	0.00454	CcSEcCtD
Crizotinib—MAP3K3—trachea—chronic obstructive pulmonary disease	0.00113	0.00338	CbGeAlD
Crizotinib—MAP4K5—trachea—chronic obstructive pulmonary disease	0.00113	0.00338	CbGeAlD
Crizotinib—LIMK2—lung—chronic obstructive pulmonary disease	0.00112	0.00337	CbGeAlD
Crizotinib—Loss of consciousness—Tiotropium—chronic obstructive pulmonary disease	0.00112	0.00449	CcSEcCtD
Crizotinib—NUAK2—lung—chronic obstructive pulmonary disease	0.00112	0.00335	CbGeAlD
Crizotinib—FLT3—lung—chronic obstructive pulmonary disease	0.00111	0.00333	CbGeAlD
Crizotinib—ACVR1—lung—chronic obstructive pulmonary disease	0.00111	0.00333	CbGeAlD
Crizotinib—MAP3K12—lung—chronic obstructive pulmonary disease	0.00111	0.00333	CbGeAlD
Crizotinib—Hypoaesthesia—Salbutamol—chronic obstructive pulmonary disease	0.00111	0.00445	CcSEcCtD
Crizotinib—Urinary tract disorder—Salbutamol—chronic obstructive pulmonary disease	0.0011	0.00442	CcSEcCtD
Crizotinib—Cardiac disorder—Formoterol—chronic obstructive pulmonary disease	0.00109	0.0044	CcSEcCtD
Crizotinib—Cardiac disorder—Arformoterol—chronic obstructive pulmonary disease	0.00109	0.0044	CcSEcCtD
Crizotinib—Infection—Aminophylline—chronic obstructive pulmonary disease	0.00109	0.0044	CcSEcCtD
Crizotinib—Dizziness—Roflumilast—chronic obstructive pulmonary disease	0.00109	0.00439	CcSEcCtD
Crizotinib—Urethral disorder—Salbutamol—chronic obstructive pulmonary disease	0.00109	0.00439	CcSEcCtD
Crizotinib—SRC—smooth muscle tissue—chronic obstructive pulmonary disease	0.00109	0.00328	CbGeAlD
Crizotinib—STK35—lung—chronic obstructive pulmonary disease	0.00109	0.00326	CbGeAlD
Crizotinib—Shock—Aminophylline—chronic obstructive pulmonary disease	0.00108	0.00435	CcSEcCtD
Crizotinib—Nervous system disorder—Aminophylline—chronic obstructive pulmonary disease	0.00108	0.00434	CcSEcCtD
Crizotinib—EPHB6—trachea—chronic obstructive pulmonary disease	0.00108	0.00323	CbGeAlD
Crizotinib—Unspecified disorder of skin and subcutaneous tissue—Tiotropium—chronic obstructive pulmonary disease	0.00108	0.00432	CcSEcCtD
Crizotinib—Cardiac disorder—Montelukast—chronic obstructive pulmonary disease	0.00107	0.00431	CcSEcCtD
Crizotinib—CSF1R—connective tissue—chronic obstructive pulmonary disease	0.00107	0.00322	CbGeAlD
Crizotinib—Mediastinal disorder—Arformoterol—chronic obstructive pulmonary disease	0.00106	0.00427	CcSEcCtD
Crizotinib—Mediastinal disorder—Formoterol—chronic obstructive pulmonary disease	0.00106	0.00427	CcSEcCtD
Crizotinib—ABL2—lung—chronic obstructive pulmonary disease	0.00106	0.00318	CbGeAlD
Crizotinib—Arrhythmia—Arformoterol—chronic obstructive pulmonary disease	0.00105	0.00424	CcSEcCtD
Crizotinib—Arrhythmia—Formoterol—chronic obstructive pulmonary disease	0.00105	0.00424	CcSEcCtD
Crizotinib—Vomiting—Roflumilast—chronic obstructive pulmonary disease	0.00105	0.00422	CcSEcCtD
Crizotinib—BMP2K—lung—chronic obstructive pulmonary disease	0.00105	0.00314	CbGeAlD
Crizotinib—Mediastinal disorder—Montelukast—chronic obstructive pulmonary disease	0.00104	0.00418	CcSEcCtD
Crizotinib—Rash—Roflumilast—chronic obstructive pulmonary disease	0.00104	0.00418	CcSEcCtD
Crizotinib—YES1—trachea—chronic obstructive pulmonary disease	0.00104	0.00313	CbGeAlD
Crizotinib—Dermatitis—Roflumilast—chronic obstructive pulmonary disease	0.00104	0.00418	CcSEcCtD
Crizotinib—Oedema—Tiotropium—chronic obstructive pulmonary disease	0.00104	0.00417	CcSEcCtD
Crizotinib—Cardiac disorder—Salbutamol—chronic obstructive pulmonary disease	0.00103	0.00415	CcSEcCtD
Crizotinib—Infection—Tiotropium—chronic obstructive pulmonary disease	0.00103	0.00415	CcSEcCtD
Crizotinib—TAOK3—trachea—chronic obstructive pulmonary disease	0.00103	0.00309	CbGeAlD
Crizotinib—Malnutrition—Arformoterol—chronic obstructive pulmonary disease	0.00103	0.00413	CcSEcCtD
Crizotinib—Malnutrition—Formoterol—chronic obstructive pulmonary disease	0.00103	0.00413	CcSEcCtD
Crizotinib—Shock—Tiotropium—chronic obstructive pulmonary disease	0.00102	0.00411	CcSEcCtD
Crizotinib—Nervous system disorder—Tiotropium—chronic obstructive pulmonary disease	0.00102	0.00409	CcSEcCtD
Crizotinib—PTK2B—lung—chronic obstructive pulmonary disease	0.00101	0.00303	CbGeAlD
Crizotinib—Skin disorder—Tiotropium—chronic obstructive pulmonary disease	0.00101	0.00405	CcSEcCtD
Crizotinib—Dysgeusia—Formoterol—chronic obstructive pulmonary disease	0.00101	0.00404	CcSEcCtD
Crizotinib—Dysgeusia—Arformoterol—chronic obstructive pulmonary disease	0.00101	0.00404	CcSEcCtD
Crizotinib—Mediastinal disorder—Salbutamol—chronic obstructive pulmonary disease	0.001	0.00403	CcSEcCtD
Crizotinib—RIPK2—lung—chronic obstructive pulmonary disease	0.001	0.00301	CbGeAlD
Crizotinib—CSF1R—bronchus—chronic obstructive pulmonary disease	0.001	0.00301	CbGeAlD
Crizotinib—Arrhythmia—Salbutamol—chronic obstructive pulmonary disease	0.000995	0.004	CcSEcCtD
Crizotinib—Nausea—Roflumilast—chronic obstructive pulmonary disease	0.000981	0.00394	CcSEcCtD
Crizotinib—CSF1R—smooth muscle tissue—chronic obstructive pulmonary disease	0.000979	0.00294	CbGeAlD
Crizotinib—Visual disturbance—Prednisolone—chronic obstructive pulmonary disease	0.000974	0.00392	CcSEcCtD
Crizotinib—Malnutrition—Salbutamol—chronic obstructive pulmonary disease	0.00097	0.0039	CcSEcCtD
Crizotinib—Dyspepsia—Aminophylline—chronic obstructive pulmonary disease	0.000969	0.0039	CcSEcCtD
Crizotinib—EPHA4—lung—chronic obstructive pulmonary disease	0.000968	0.00291	CbGeAlD
Crizotinib—ABL1—respiratory system—chronic obstructive pulmonary disease	0.000962	0.00289	CbGeAlD
Crizotinib—Decreased appetite—Aminophylline—chronic obstructive pulmonary disease	0.000957	0.00385	CcSEcCtD
Crizotinib—Dysgeusia—Salbutamol—chronic obstructive pulmonary disease	0.000949	0.00382	CcSEcCtD
Crizotinib—MAP3K2—lung—chronic obstructive pulmonary disease	0.000949	0.00285	CbGeAlD
Crizotinib—ACVR1—Dexamethasone—Prednisone—chronic obstructive pulmonary disease	0.00094	0.154	CbGdCrCtD
Crizotinib—ACVR1—Betamethasone—Prednisone—chronic obstructive pulmonary disease	0.00094	0.154	CbGdCrCtD
Crizotinib—Paraesthesia—Tiotropium—chronic obstructive pulmonary disease	0.000932	0.00375	CcSEcCtD
Crizotinib—PTK2—lung—chronic obstructive pulmonary disease	0.00093	0.00279	CbGeAlD
Crizotinib—TBK1—lung—chronic obstructive pulmonary disease	0.00093	0.00279	CbGeAlD
Crizotinib—TYK2—lung—chronic obstructive pulmonary disease	0.000923	0.00277	CbGeAlD
Crizotinib—ACVR1—Dexamethasone—Prednisolone—chronic obstructive pulmonary disease	0.000917	0.15	CbGdCrCtD
Crizotinib—ACVR1—Betamethasone—Prednisolone—chronic obstructive pulmonary disease	0.000917	0.15	CbGdCrCtD
Crizotinib—Dyspepsia—Tiotropium—chronic obstructive pulmonary disease	0.000914	0.00367	CcSEcCtD
Crizotinib—IRAK1—lung—chronic obstructive pulmonary disease	0.000911	0.00274	CbGeAlD
Crizotinib—CSF1R—trachea—chronic obstructive pulmonary disease	0.000899	0.0027	CbGeAlD
Crizotinib—Gastrointestinal disorder—Tiotropium—chronic obstructive pulmonary disease	0.000896	0.0036	CcSEcCtD
Crizotinib—RPS6KB1—lung—chronic obstructive pulmonary disease	0.000894	0.00269	CbGeAlD
Crizotinib—LCK—lung—chronic obstructive pulmonary disease	0.000889	0.00267	CbGeAlD
Crizotinib—FGR—lung—chronic obstructive pulmonary disease	0.000889	0.00267	CbGeAlD
Crizotinib—Constipation—Tiotropium—chronic obstructive pulmonary disease	0.000888	0.00357	CcSEcCtD
Crizotinib—AXL—lung—chronic obstructive pulmonary disease	0.000885	0.00266	CbGeAlD
Crizotinib—Fluid retention—Prednisone—chronic obstructive pulmonary disease	0.000878	0.00353	CcSEcCtD
Crizotinib—Body temperature increased—Aminophylline—chronic obstructive pulmonary disease	0.00087	0.0035	CcSEcCtD
Crizotinib—Syncope—Salbutamol—chronic obstructive pulmonary disease	0.000869	0.00349	CcSEcCtD
Crizotinib—Unspecified disorder of skin and subcutaneous tissue—Formoterol—chronic obstructive pulmonary disease	0.000868	0.00349	CcSEcCtD
Crizotinib—Unspecified disorder of skin and subcutaneous tissue—Arformoterol—chronic obstructive pulmonary disease	0.000868	0.00349	CcSEcCtD
Crizotinib—Neuropathy—Prednisone—chronic obstructive pulmonary disease	0.000868	0.00349	CcSEcCtD
Crizotinib—SLK—lung—chronic obstructive pulmonary disease	0.000852	0.00256	CbGeAlD
Crizotinib—Loss of consciousness—Salbutamol—chronic obstructive pulmonary disease	0.000852	0.00342	CcSEcCtD
Crizotinib—Unspecified disorder of skin and subcutaneous tissue—Montelukast—chronic obstructive pulmonary disease	0.00085	0.00342	CcSEcCtD
Crizotinib—ABL1—connective tissue—chronic obstructive pulmonary disease	0.000846	0.00254	CbGeAlD
Crizotinib—EPHB4—lung—chronic obstructive pulmonary disease	0.000846	0.00254	CbGeAlD
Crizotinib—JAK2—lung—chronic obstructive pulmonary disease	0.00084	0.00252	CbGeAlD
Crizotinib—Oedema—Formoterol—chronic obstructive pulmonary disease	0.000838	0.00337	CcSEcCtD
Crizotinib—Oedema—Arformoterol—chronic obstructive pulmonary disease	0.000838	0.00337	CcSEcCtD
Crizotinib—Infection—Arformoterol—chronic obstructive pulmonary disease	0.000833	0.00335	CcSEcCtD
Crizotinib—Infection—Formoterol—chronic obstructive pulmonary disease	0.000833	0.00335	CcSEcCtD
Crizotinib—EPHA2—lung—chronic obstructive pulmonary disease	0.00083	0.00249	CbGeAlD
Crizotinib—Nervous system disorder—Arformoterol—chronic obstructive pulmonary disease	0.000822	0.0033	CcSEcCtD
Crizotinib—Nervous system disorder—Formoterol—chronic obstructive pulmonary disease	0.000822	0.0033	CcSEcCtD
Crizotinib—Oedema—Montelukast—chronic obstructive pulmonary disease	0.000821	0.0033	CcSEcCtD
Crizotinib—Infection—Montelukast—chronic obstructive pulmonary disease	0.000815	0.00328	CcSEcCtD
Crizotinib—Muscular weakness—Prednisolone—chronic obstructive pulmonary disease	0.000814	0.00327	CcSEcCtD
Crizotinib—Skin disorder—Arformoterol—chronic obstructive pulmonary disease	0.000814	0.00327	CcSEcCtD
Crizotinib—Skin disorder—Formoterol—chronic obstructive pulmonary disease	0.000814	0.00327	CcSEcCtD
Crizotinib—TEK—lung—chronic obstructive pulmonary disease	0.00081	0.00243	CbGeAlD
Crizotinib—MAP3K3—lung—chronic obstructive pulmonary disease	0.00081	0.00243	CbGeAlD
Crizotinib—MAP4K5—lung—chronic obstructive pulmonary disease	0.00081	0.00243	CbGeAlD
Crizotinib—Nervous system disorder—Montelukast—chronic obstructive pulmonary disease	0.000805	0.00324	CcSEcCtD
Crizotinib—Sepsis—Prednisone—chronic obstructive pulmonary disease	0.000802	0.00322	CcSEcCtD
Crizotinib—Skin disorder—Montelukast—chronic obstructive pulmonary disease	0.000797	0.0032	CcSEcCtD
Crizotinib—ABL1—bronchus—chronic obstructive pulmonary disease	0.000791	0.00238	CbGeAlD
Crizotinib—Oedema—Salbutamol—chronic obstructive pulmonary disease	0.000791	0.00318	CcSEcCtD
Crizotinib—Infection—Salbutamol—chronic obstructive pulmonary disease	0.000786	0.00316	CcSEcCtD
Crizotinib—Shock—Salbutamol—chronic obstructive pulmonary disease	0.000779	0.00313	CcSEcCtD
Crizotinib—Nervous system disorder—Salbutamol—chronic obstructive pulmonary disease	0.000776	0.00312	CcSEcCtD
Crizotinib—ABL1—smooth muscle tissue—chronic obstructive pulmonary disease	0.000774	0.00233	CbGeAlD
Crizotinib—EPHB6—lung—chronic obstructive pulmonary disease	0.000774	0.00232	CbGeAlD
Crizotinib—Skin disorder—Salbutamol—chronic obstructive pulmonary disease	0.000769	0.00309	CcSEcCtD
Crizotinib—Diarrhoea—Aminophylline—chronic obstructive pulmonary disease	0.000753	0.00303	CcSEcCtD
Crizotinib—YES1—lung—chronic obstructive pulmonary disease	0.000748	0.00225	CbGeAlD
Crizotinib—Dyspnoea—Formoterol—chronic obstructive pulmonary disease	0.000747	0.003	CcSEcCtD
Crizotinib—Dyspnoea—Arformoterol—chronic obstructive pulmonary disease	0.000747	0.003	CcSEcCtD
Crizotinib—STK10—lung—chronic obstructive pulmonary disease	0.000741	0.00223	CbGeAlD
Crizotinib—TAOK3—lung—chronic obstructive pulmonary disease	0.000738	0.00222	CbGeAlD
Crizotinib—Dyspepsia—Formoterol—chronic obstructive pulmonary disease	0.000738	0.00296	CcSEcCtD
Crizotinib—Dyspepsia—Arformoterol—chronic obstructive pulmonary disease	0.000738	0.00296	CcSEcCtD
Crizotinib—Paraesthesia—Montelukast—chronic obstructive pulmonary disease	0.000737	0.00296	CcSEcCtD
Crizotinib—Dizziness—Aminophylline—chronic obstructive pulmonary disease	0.000728	0.00293	CcSEcCtD
Crizotinib—Gastrointestinal disorder—Arformoterol—chronic obstructive pulmonary disease	0.000724	0.00291	CcSEcCtD
Crizotinib—Gastrointestinal disorder—Formoterol—chronic obstructive pulmonary disease	0.000724	0.00291	CcSEcCtD
Crizotinib—Dyspepsia—Montelukast—chronic obstructive pulmonary disease	0.000723	0.0029	CcSEcCtD
Crizotinib—Fatigue—Formoterol—chronic obstructive pulmonary disease	0.000723	0.0029	CcSEcCtD
Crizotinib—Fatigue—Arformoterol—chronic obstructive pulmonary disease	0.000723	0.0029	CcSEcCtD
Crizotinib—SRC—lung—chronic obstructive pulmonary disease	0.000719	0.00216	CbGeAlD
Crizotinib—Constipation—Arformoterol—chronic obstructive pulmonary disease	0.000717	0.00288	CcSEcCtD
Crizotinib—Constipation—Formoterol—chronic obstructive pulmonary disease	0.000717	0.00288	CcSEcCtD
Crizotinib—ABL1—trachea—chronic obstructive pulmonary disease	0.000711	0.00213	CbGeAlD
Crizotinib—Paraesthesia—Salbutamol—chronic obstructive pulmonary disease	0.000711	0.00286	CcSEcCtD
Crizotinib—Gastrointestinal disorder—Montelukast—chronic obstructive pulmonary disease	0.000709	0.00285	CcSEcCtD
Crizotinib—Fatigue—Montelukast—chronic obstructive pulmonary disease	0.000708	0.00284	CcSEcCtD
Crizotinib—Dyspnoea—Salbutamol—chronic obstructive pulmonary disease	0.000705	0.00284	CcSEcCtD
Crizotinib—Vomiting—Aminophylline—chronic obstructive pulmonary disease	0.0007	0.00281	CcSEcCtD
Crizotinib—Neuropathy peripheral—Prednisolone—chronic obstructive pulmonary disease	0.000698	0.0028	CcSEcCtD
Crizotinib—Dyspepsia—Salbutamol—chronic obstructive pulmonary disease	0.000697	0.0028	CcSEcCtD
Crizotinib—Rash—Aminophylline—chronic obstructive pulmonary disease	0.000694	0.00279	CcSEcCtD
Crizotinib—Dermatitis—Aminophylline—chronic obstructive pulmonary disease	0.000694	0.00279	CcSEcCtD
Crizotinib—Decreased appetite—Salbutamol—chronic obstructive pulmonary disease	0.000688	0.00276	CcSEcCtD
Crizotinib—Dizziness—Tiotropium—chronic obstructive pulmonary disease	0.000687	0.00276	CcSEcCtD
Crizotinib—Gastrointestinal disorder—Salbutamol—chronic obstructive pulmonary disease	0.000683	0.00275	CcSEcCtD
Crizotinib—Fatigue—Salbutamol—chronic obstructive pulmonary disease	0.000682	0.00274	CcSEcCtD
Crizotinib—Constipation—Salbutamol—chronic obstructive pulmonary disease	0.000677	0.00272	CcSEcCtD
Crizotinib—Body temperature increased—Arformoterol—chronic obstructive pulmonary disease	0.000662	0.00266	CcSEcCtD
Crizotinib—Body temperature increased—Formoterol—chronic obstructive pulmonary disease	0.000662	0.00266	CcSEcCtD
Crizotinib—Vomiting—Tiotropium—chronic obstructive pulmonary disease	0.00066	0.00265	CcSEcCtD
Crizotinib—Rash—Tiotropium—chronic obstructive pulmonary disease	0.000655	0.00263	CcSEcCtD
Crizotinib—Dermatitis—Tiotropium—chronic obstructive pulmonary disease	0.000654	0.00263	CcSEcCtD
Crizotinib—Nausea—Aminophylline—chronic obstructive pulmonary disease	0.000654	0.00263	CcSEcCtD
Crizotinib—Bradycardia—Prednisolone—chronic obstructive pulmonary disease	0.00065	0.00261	CcSEcCtD
Crizotinib—Body temperature increased—Montelukast—chronic obstructive pulmonary disease	0.000649	0.00261	CcSEcCtD
Crizotinib—Face oedema—Prednisone—chronic obstructive pulmonary disease	0.000648	0.0026	CcSEcCtD
Crizotinib—CSF1R—lung—chronic obstructive pulmonary disease	0.000646	0.00194	CbGeAlD
Crizotinib—Body temperature increased—Salbutamol—chronic obstructive pulmonary disease	0.000626	0.00251	CcSEcCtD
Crizotinib—Nausea—Tiotropium—chronic obstructive pulmonary disease	0.000617	0.00248	CcSEcCtD
Crizotinib—Visual impairment—Prednisolone—chronic obstructive pulmonary disease	0.000616	0.00247	CcSEcCtD
Crizotinib—Hypokalaemia—Prednisone—chronic obstructive pulmonary disease	0.000611	0.00245	CcSEcCtD
Crizotinib—TESK1—Dexamethasone—Prednisone—chronic obstructive pulmonary disease	0.000605	0.0992	CbGdCrCtD
Crizotinib—TESK1—Betamethasone—Prednisone—chronic obstructive pulmonary disease	0.000605	0.0992	CbGdCrCtD
Crizotinib—Asthenia—Arformoterol—chronic obstructive pulmonary disease	0.000601	0.00242	CcSEcCtD
Crizotinib—Asthenia—Formoterol—chronic obstructive pulmonary disease	0.000601	0.00242	CcSEcCtD
Crizotinib—Muscular weakness—Prednisone—chronic obstructive pulmonary disease	0.000592	0.00238	CcSEcCtD
Crizotinib—Alanine aminotransferase increased—Prednisone—chronic obstructive pulmonary disease	0.000592	0.00238	CcSEcCtD
Crizotinib—TESK1—Betamethasone—Prednisolone—chronic obstructive pulmonary disease	0.000591	0.0968	CbGdCrCtD
Crizotinib—TESK1—Dexamethasone—Prednisolone—chronic obstructive pulmonary disease	0.000591	0.0968	CbGdCrCtD
Crizotinib—Asthenia—Montelukast—chronic obstructive pulmonary disease	0.000589	0.00237	CcSEcCtD
Crizotinib—Diarrhoea—Formoterol—chronic obstructive pulmonary disease	0.000573	0.0023	CcSEcCtD
Crizotinib—Diarrhoea—Arformoterol—chronic obstructive pulmonary disease	0.000573	0.0023	CcSEcCtD
Crizotinib—Arrhythmia—Prednisolone—chronic obstructive pulmonary disease	0.000571	0.00229	CcSEcCtD
Crizotinib—Asthenia—Salbutamol—chronic obstructive pulmonary disease	0.000568	0.00228	CcSEcCtD
Crizotinib—CYP3A5—respiratory system—chronic obstructive pulmonary disease	0.000563	0.00169	CbGeAlD
Crizotinib—Diarrhoea—Montelukast—chronic obstructive pulmonary disease	0.000562	0.00226	CcSEcCtD
Crizotinib—Dizziness—Arformoterol—chronic obstructive pulmonary disease	0.000554	0.00223	CcSEcCtD
Crizotinib—Dizziness—Formoterol—chronic obstructive pulmonary disease	0.000554	0.00223	CcSEcCtD
Crizotinib—Dizziness—Montelukast—chronic obstructive pulmonary disease	0.000543	0.00218	CcSEcCtD
Crizotinib—Neutropenia—Prednisone—chronic obstructive pulmonary disease	0.000542	0.00218	CcSEcCtD
Crizotinib—Diarrhoea—Salbutamol—chronic obstructive pulmonary disease	0.000541	0.00218	CcSEcCtD
Crizotinib—Vomiting—Arformoterol—chronic obstructive pulmonary disease	0.000533	0.00214	CcSEcCtD
Crizotinib—Vomiting—Formoterol—chronic obstructive pulmonary disease	0.000533	0.00214	CcSEcCtD
Crizotinib—Rash—Formoterol—chronic obstructive pulmonary disease	0.000528	0.00212	CcSEcCtD
Crizotinib—Rash—Arformoterol—chronic obstructive pulmonary disease	0.000528	0.00212	CcSEcCtD
Crizotinib—Dermatitis—Formoterol—chronic obstructive pulmonary disease	0.000528	0.00212	CcSEcCtD
Crizotinib—Dermatitis—Arformoterol—chronic obstructive pulmonary disease	0.000528	0.00212	CcSEcCtD
Crizotinib—Weight decreased—Prednisone—chronic obstructive pulmonary disease	0.000525	0.00211	CcSEcCtD
Crizotinib—Vision blurred—Prednisolone—chronic obstructive pulmonary disease	0.000524	0.00211	CcSEcCtD
Crizotinib—Dizziness—Salbutamol—chronic obstructive pulmonary disease	0.000523	0.0021	CcSEcCtD
Crizotinib—Vomiting—Montelukast—chronic obstructive pulmonary disease	0.000522	0.0021	CcSEcCtD
Crizotinib—Rash—Montelukast—chronic obstructive pulmonary disease	0.000518	0.00208	CcSEcCtD
Crizotinib—Dermatitis—Montelukast—chronic obstructive pulmonary disease	0.000517	0.00208	CcSEcCtD
Crizotinib—ABL1—lung—chronic obstructive pulmonary disease	0.000511	0.00153	CbGeAlD
Crizotinib—Neuropathy peripheral—Prednisone—chronic obstructive pulmonary disease	0.000507	0.00204	CcSEcCtD
Crizotinib—Vomiting—Salbutamol—chronic obstructive pulmonary disease	0.000503	0.00202	CcSEcCtD
Crizotinib—Rash—Salbutamol—chronic obstructive pulmonary disease	0.000499	0.00201	CcSEcCtD
Crizotinib—Syncope—Prednisolone—chronic obstructive pulmonary disease	0.000499	0.002	CcSEcCtD
Crizotinib—Dermatitis—Salbutamol—chronic obstructive pulmonary disease	0.000498	0.002	CcSEcCtD
Crizotinib—Nausea—Formoterol—chronic obstructive pulmonary disease	0.000498	0.002	CcSEcCtD
Crizotinib—Nausea—Arformoterol—chronic obstructive pulmonary disease	0.000498	0.002	CcSEcCtD
Crizotinib—Loss of consciousness—Prednisolone—chronic obstructive pulmonary disease	0.000489	0.00196	CcSEcCtD
Crizotinib—Nausea—Montelukast—chronic obstructive pulmonary disease	0.000488	0.00196	CcSEcCtD
Crizotinib—Bradycardia—Prednisone—chronic obstructive pulmonary disease	0.000473	0.0019	CcSEcCtD
Crizotinib—Nausea—Salbutamol—chronic obstructive pulmonary disease	0.00047	0.00189	CcSEcCtD
Crizotinib—Oedema—Prednisolone—chronic obstructive pulmonary disease	0.000454	0.00182	CcSEcCtD
Crizotinib—Shock—Prednisolone—chronic obstructive pulmonary disease	0.000447	0.00179	CcSEcCtD
Crizotinib—Eye disorder—Prednisone—chronic obstructive pulmonary disease	0.000434	0.00174	CcSEcCtD
Crizotinib—Arrhythmia—Prednisone—chronic obstructive pulmonary disease	0.000415	0.00167	CcSEcCtD
Crizotinib—Paraesthesia—Prednisolone—chronic obstructive pulmonary disease	0.000408	0.00164	CcSEcCtD
Crizotinib—Malnutrition—Prednisone—chronic obstructive pulmonary disease	0.000404	0.00162	CcSEcCtD
Crizotinib—Vision blurred—Prednisone—chronic obstructive pulmonary disease	0.000381	0.00153	CcSEcCtD
Crizotinib—Anaemia—Prednisone—chronic obstructive pulmonary disease	0.000373	0.0015	CcSEcCtD
Crizotinib—Syncope—Prednisone—chronic obstructive pulmonary disease	0.000362	0.00146	CcSEcCtD
Crizotinib—Loss of consciousness—Prednisone—chronic obstructive pulmonary disease	0.000355	0.00143	CcSEcCtD
Crizotinib—Unspecified disorder of skin and subcutaneous tissue—Prednisone—chronic obstructive pulmonary disease	0.000342	0.00137	CcSEcCtD
Crizotinib—Oedema—Prednisone—chronic obstructive pulmonary disease	0.00033	0.00133	CcSEcCtD
Crizotinib—Infection—Prednisone—chronic obstructive pulmonary disease	0.000328	0.00132	CcSEcCtD
Crizotinib—Shock—Prednisone—chronic obstructive pulmonary disease	0.000324	0.0013	CcSEcCtD
Crizotinib—Nervous system disorder—Prednisone—chronic obstructive pulmonary disease	0.000323	0.0013	CcSEcCtD
Crizotinib—Skin disorder—Prednisone—chronic obstructive pulmonary disease	0.00032	0.00129	CcSEcCtD
Crizotinib—Dizziness—Prednisolone—chronic obstructive pulmonary disease	0.0003	0.00121	CcSEcCtD
Crizotinib—ABCB1—respiratory system—chronic obstructive pulmonary disease	0.000299	0.000898	CbGeAlD
Crizotinib—CYP3A5—lung—chronic obstructive pulmonary disease	0.000299	0.000898	CbGeAlD
Crizotinib—Paraesthesia—Prednisone—chronic obstructive pulmonary disease	0.000296	0.00119	CcSEcCtD
Crizotinib—Dyspepsia—Prednisone—chronic obstructive pulmonary disease	0.00029	0.00117	CcSEcCtD
Crizotinib—Decreased appetite—Prednisone—chronic obstructive pulmonary disease	0.000287	0.00115	CcSEcCtD
Crizotinib—Rash—Prednisolone—chronic obstructive pulmonary disease	0.000286	0.00115	CcSEcCtD
Crizotinib—Dermatitis—Prednisolone—chronic obstructive pulmonary disease	0.000286	0.00115	CcSEcCtD
Crizotinib—Fatigue—Prednisone—chronic obstructive pulmonary disease	0.000284	0.00114	CcSEcCtD
Crizotinib—Constipation—Prednisone—chronic obstructive pulmonary disease	0.000282	0.00113	CcSEcCtD
Crizotinib—Nausea—Prednisolone—chronic obstructive pulmonary disease	0.00027	0.00108	CcSEcCtD
Crizotinib—Body temperature increased—Prednisone—chronic obstructive pulmonary disease	0.000261	0.00105	CcSEcCtD
Crizotinib—Asthenia—Prednisone—chronic obstructive pulmonary disease	0.000237	0.000951	CcSEcCtD
Crizotinib—Diarrhoea—Prednisone—chronic obstructive pulmonary disease	0.000226	0.000907	CcSEcCtD
Crizotinib—ABCB1—trachea—chronic obstructive pulmonary disease	0.000221	0.000664	CbGeAlD
Crizotinib—Dizziness—Prednisone—chronic obstructive pulmonary disease	0.000218	0.000877	CcSEcCtD
Crizotinib—Vomiting—Prednisone—chronic obstructive pulmonary disease	0.00021	0.000843	CcSEcCtD
Crizotinib—Rash—Prednisone—chronic obstructive pulmonary disease	0.000208	0.000836	CcSEcCtD
Crizotinib—Dermatitis—Prednisone—chronic obstructive pulmonary disease	0.000208	0.000835	CcSEcCtD
Crizotinib—Nausea—Prednisone—chronic obstructive pulmonary disease	0.000196	0.000787	CcSEcCtD
Crizotinib—ABCB1—lung—chronic obstructive pulmonary disease	0.000159	0.000477	CbGeAlD
Crizotinib—JAK2—Innate Immune System—EGFR—chronic obstructive pulmonary disease	1.2e-05	2.92e-05	CbGpPWpGaD
Crizotinib—LYN—Hemostasis—TP53—chronic obstructive pulmonary disease	1.2e-05	2.91e-05	CbGpPWpGaD
Crizotinib—LCK—Hemostasis—TGFB1—chronic obstructive pulmonary disease	1.19e-05	2.9e-05	CbGpPWpGaD
Crizotinib—ABL1—Hemostasis—TP53—chronic obstructive pulmonary disease	1.19e-05	2.9e-05	CbGpPWpGaD
Crizotinib—MAP3K3—Immune System—IL6—chronic obstructive pulmonary disease	1.19e-05	2.88e-05	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	1.18e-05	2.87e-05	CbGpPWpGaD
Crizotinib—SRC—Developmental Biology—VEGFA—chronic obstructive pulmonary disease	1.17e-05	2.85e-05	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—CTGF—chronic obstructive pulmonary disease	1.17e-05	2.83e-05	CbGpPWpGaD
Crizotinib—JAK3—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	1.17e-05	2.83e-05	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—HDAC2—chronic obstructive pulmonary disease	1.16e-05	2.82e-05	CbGpPWpGaD
Crizotinib—JAK2—GPCR downstream signaling—CXCL8—chronic obstructive pulmonary disease	1.16e-05	2.81e-05	CbGpPWpGaD
Crizotinib—SRC—Disease—ERBB3—chronic obstructive pulmonary disease	1.15e-05	2.8e-05	CbGpPWpGaD
Crizotinib—SRC—Hemostasis—VEGFA—chronic obstructive pulmonary disease	1.15e-05	2.8e-05	CbGpPWpGaD
Crizotinib—RIPK2—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	1.15e-05	2.79e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—EDN1—chronic obstructive pulmonary disease	1.15e-05	2.78e-05	CbGpPWpGaD
Crizotinib—SRC—Immune System—CRP—chronic obstructive pulmonary disease	1.14e-05	2.78e-05	CbGpPWpGaD
Crizotinib—SRC—Axon guidance—IL6—chronic obstructive pulmonary disease	1.14e-05	2.76e-05	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	1.13e-05	2.75e-05	CbGpPWpGaD
Crizotinib—PTK2B—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	1.13e-05	2.75e-05	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—ADRB2—chronic obstructive pulmonary disease	1.12e-05	2.73e-05	CbGpPWpGaD
Crizotinib—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—chronic obstructive pulmonary disease	1.12e-05	2.72e-05	CbGpPWpGaD
Crizotinib—JAK2—Hemostasis—TP53—chronic obstructive pulmonary disease	1.12e-05	2.72e-05	CbGpPWpGaD
Crizotinib—JAK3—Immune System—IL6—chronic obstructive pulmonary disease	1.12e-05	2.72e-05	CbGpPWpGaD
Crizotinib—LYN—Developmental Biology—IL6—chronic obstructive pulmonary disease	1.12e-05	2.72e-05	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—ERBB3—chronic obstructive pulmonary disease	1.11e-05	2.7e-05	CbGpPWpGaD
Crizotinib—ABL1—Developmental Biology—IL6—chronic obstructive pulmonary disease	1.11e-05	2.7e-05	CbGpPWpGaD
Crizotinib—FES—Signaling Pathways—IL6—chronic obstructive pulmonary disease	1.11e-05	2.69e-05	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—GC—chronic obstructive pulmonary disease	1.1e-05	2.67e-05	CbGpPWpGaD
Crizotinib—SRC—Immune System—TLR4—chronic obstructive pulmonary disease	1.1e-05	2.66e-05	CbGpPWpGaD
Crizotinib—IGF1R—Signaling Pathways—TP53—chronic obstructive pulmonary disease	1.09e-05	2.65e-05	CbGpPWpGaD
Crizotinib—LCK—Disease—NOS2—chronic obstructive pulmonary disease	1.09e-05	2.64e-05	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	1.08e-05	2.63e-05	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—KL—chronic obstructive pulmonary disease	1.08e-05	2.62e-05	CbGpPWpGaD
Crizotinib—SRC—Developmental Biology—TGFB1—chronic obstructive pulmonary disease	1.08e-05	2.62e-05	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—CYP1A2—chronic obstructive pulmonary disease	1.08e-05	2.61e-05	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—HTR2A—chronic obstructive pulmonary disease	1.07e-05	2.6e-05	CbGpPWpGaD
Crizotinib—MAPK7—Signaling Pathways—TP53—chronic obstructive pulmonary disease	1.07e-05	2.6e-05	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—SERPINE1—chronic obstructive pulmonary disease	1.06e-05	2.58e-05	CbGpPWpGaD
Crizotinib—SRC—Hemostasis—TGFB1—chronic obstructive pulmonary disease	1.06e-05	2.57e-05	CbGpPWpGaD
Crizotinib—SRC—Developmental Biology—EGFR—chronic obstructive pulmonary disease	1.06e-05	2.56e-05	CbGpPWpGaD
Crizotinib—LCK—Innate Immune System—EGFR—chronic obstructive pulmonary disease	1.05e-05	2.56e-05	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	1.05e-05	2.55e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling by GPCR—CXCL8—chronic obstructive pulmonary disease	1.05e-05	2.55e-05	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—SERPINE1—chronic obstructive pulmonary disease	1.05e-05	2.55e-05	CbGpPWpGaD
Crizotinib—JAK2—Developmental Biology—IL6—chronic obstructive pulmonary disease	1.05e-05	2.54e-05	CbGpPWpGaD
Crizotinib—JAK3—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	1.05e-05	2.54e-05	CbGpPWpGaD
Crizotinib—JAK2—Disease—SERPINE1—chronic obstructive pulmonary disease	1.05e-05	2.54e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—ERBB3—chronic obstructive pulmonary disease	1.04e-05	2.53e-05	CbGpPWpGaD
Crizotinib—RIPK2—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	1.04e-05	2.52e-05	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	1.02e-05	2.49e-05	CbGpPWpGaD
Crizotinib—PTK2B—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	1.02e-05	2.48e-05	CbGpPWpGaD
Crizotinib—PTK2—Immune System—EGFR—chronic obstructive pulmonary disease	1.02e-05	2.47e-05	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	1.02e-05	2.47e-05	CbGpPWpGaD
Crizotinib—TYK2—Signaling by GPCR—EGFR—chronic obstructive pulmonary disease	1.01e-05	2.46e-05	CbGpPWpGaD
Crizotinib—LCK—Adaptive Immune System—EGFR—chronic obstructive pulmonary disease	1.01e-05	2.46e-05	CbGpPWpGaD
Crizotinib—SRC—Developmental Biology—TNF—chronic obstructive pulmonary disease	1.01e-05	2.44e-05	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—EDN1—chronic obstructive pulmonary disease	1.01e-05	2.44e-05	CbGpPWpGaD
Crizotinib—YES1—Immune System—EGFR—chronic obstructive pulmonary disease	1e-05	2.44e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—HTR2A—chronic obstructive pulmonary disease	1e-05	2.44e-05	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	1e-05	2.43e-05	CbGpPWpGaD
Crizotinib—IGF1R—Signaling Pathways—IL6—chronic obstructive pulmonary disease	1e-05	2.43e-05	CbGpPWpGaD
Crizotinib—JAK2—Disease—NOS3—chronic obstructive pulmonary disease	9.98e-06	2.42e-05	CbGpPWpGaD
Crizotinib—RIPK2—Immune System—IL6—chronic obstructive pulmonary disease	9.98e-06	2.42e-05	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—LEP—chronic obstructive pulmonary disease	9.97e-06	2.42e-05	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—ADRB2—chronic obstructive pulmonary disease	9.96e-06	2.42e-05	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—SERPINE1—chronic obstructive pulmonary disease	9.95e-06	2.42e-05	CbGpPWpGaD
Crizotinib—LYN—Innate Immune System—IL6—chronic obstructive pulmonary disease	9.89e-06	2.4e-05	CbGpPWpGaD
Crizotinib—ABL1—Innate Immune System—IL6—chronic obstructive pulmonary disease	9.84e-06	2.39e-05	CbGpPWpGaD
Crizotinib—PTK2B—Immune System—IL6—chronic obstructive pulmonary disease	9.83e-06	2.39e-05	CbGpPWpGaD
Crizotinib—LCK—Hemostasis—TP53—chronic obstructive pulmonary disease	9.83e-06	2.39e-05	CbGpPWpGaD
Crizotinib—LYN—Immune System—IL1B—chronic obstructive pulmonary disease	9.83e-06	2.39e-05	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	9.8e-06	2.38e-05	CbGpPWpGaD
Crizotinib—MAPK7—Signaling Pathways—IL6—chronic obstructive pulmonary disease	9.8e-06	2.38e-05	CbGpPWpGaD
Crizotinib—ABL1—Immune System—IL1B—chronic obstructive pulmonary disease	9.79e-06	2.38e-05	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—GSTT1—chronic obstructive pulmonary disease	9.77e-06	2.37e-05	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—SERPINE1—chronic obstructive pulmonary disease	9.66e-06	2.34e-05	CbGpPWpGaD
Crizotinib—CDK7—Disease—IL6—chronic obstructive pulmonary disease	9.66e-06	2.34e-05	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—GCLC—chronic obstructive pulmonary disease	9.66e-06	2.34e-05	CbGpPWpGaD
Crizotinib—SRC—Disease—NOS2—chronic obstructive pulmonary disease	9.63e-06	2.34e-05	CbGpPWpGaD
Crizotinib—JAK3—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	9.61e-06	2.33e-05	CbGpPWpGaD
Crizotinib—BLK—Immune System—IL6—chronic obstructive pulmonary disease	9.6e-06	2.33e-05	CbGpPWpGaD
Crizotinib—FGR—Immune System—IL6—chronic obstructive pulmonary disease	9.57e-06	2.32e-05	CbGpPWpGaD
Crizotinib—IRAK1—Immune System—EGFR—chronic obstructive pulmonary disease	9.53e-06	2.31e-05	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	9.5e-06	2.31e-05	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	9.5e-06	2.31e-05	CbGpPWpGaD
Crizotinib—JAK3—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	9.42e-06	2.29e-05	CbGpPWpGaD
Crizotinib—SRC—Innate Immune System—EGFR—chronic obstructive pulmonary disease	9.33e-06	2.27e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—LEP—chronic obstructive pulmonary disease	9.33e-06	2.26e-05	CbGpPWpGaD
Crizotinib—RIPK2—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	9.33e-06	2.26e-05	CbGpPWpGaD
Crizotinib—JAK2—Innate Immune System—IL6—chronic obstructive pulmonary disease	9.25e-06	2.25e-05	CbGpPWpGaD
Crizotinib—TYK2—Immune System—EGFR—chronic obstructive pulmonary disease	9.25e-06	2.25e-05	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	9.23e-06	2.24e-05	CbGpPWpGaD
Crizotinib—JAK2—Immune System—IL1B—chronic obstructive pulmonary disease	9.2e-06	2.23e-05	CbGpPWpGaD
Crizotinib—PTK2B—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	9.19e-06	2.23e-05	CbGpPWpGaD
Crizotinib—LCK—Disease—SERPINE1—chronic obstructive pulmonary disease	9.16e-06	2.22e-05	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—ERBB3—chronic obstructive pulmonary disease	9.14e-06	2.22e-05	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	9.01e-06	2.19e-05	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—GSTP1—chronic obstructive pulmonary disease	8.97e-06	2.18e-05	CbGpPWpGaD
Crizotinib—SRC—Adaptive Immune System—EGFR—chronic obstructive pulmonary disease	8.96e-06	2.18e-05	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—EDN1—chronic obstructive pulmonary disease	8.9e-06	2.16e-05	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	8.89e-06	2.16e-05	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—HMOX1—chronic obstructive pulmonary disease	8.85e-06	2.15e-05	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—CTGF—chronic obstructive pulmonary disease	8.81e-06	2.14e-05	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	8.8e-06	2.14e-05	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—HTR2A—chronic obstructive pulmonary disease	8.79e-06	2.13e-05	CbGpPWpGaD
Crizotinib—LCK—Disease—NOS3—chronic obstructive pulmonary disease	8.75e-06	2.12e-05	CbGpPWpGaD
Crizotinib—TYK2—Disease—TGFB1—chronic obstructive pulmonary disease	8.71e-06	2.11e-05	CbGpPWpGaD
Crizotinib—SRC—Hemostasis—TP53—chronic obstructive pulmonary disease	8.71e-06	2.11e-05	CbGpPWpGaD
Crizotinib—ABCB1—Transmembrane transport of small molecules—ALB—chronic obstructive pulmonary disease	8.56e-06	2.08e-05	CbGpPWpGaD
Crizotinib—RIPK2—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	8.56e-06	2.08e-05	CbGpPWpGaD
Crizotinib—TYK2—Disease—EGFR—chronic obstructive pulmonary disease	8.54e-06	2.07e-05	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	8.53e-06	2.07e-05	CbGpPWpGaD
Crizotinib—PTK2B—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	8.44e-06	2.05e-05	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	8.43e-06	2.05e-05	CbGpPWpGaD
Crizotinib—RIPK2—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	8.39e-06	2.04e-05	CbGpPWpGaD
Crizotinib—PTK2B—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	8.27e-06	2.01e-05	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—GSTM1—chronic obstructive pulmonary disease	8.25e-06	2e-05	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	8.18e-06	1.99e-05	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—LEP—chronic obstructive pulmonary disease	8.17e-06	1.98e-05	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	8.15e-06	1.98e-05	CbGpPWpGaD
Crizotinib—SRC—Developmental Biology—IL6—chronic obstructive pulmonary disease	8.12e-06	1.97e-05	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—CYP1A2—chronic obstructive pulmonary disease	8.12e-06	1.97e-05	CbGpPWpGaD
Crizotinib—SRC—Disease—SERPINE1—chronic obstructive pulmonary disease	8.11e-06	1.97e-05	CbGpPWpGaD
Crizotinib—LCK—Innate Immune System—IL6—chronic obstructive pulmonary disease	8.1e-06	1.97e-05	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—ERBB3—chronic obstructive pulmonary disease	8.09e-06	1.96e-05	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	8.08e-06	1.96e-05	CbGpPWpGaD
Crizotinib—LCK—Immune System—IL1B—chronic obstructive pulmonary disease	8.06e-06	1.96e-05	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	8.04e-06	1.95e-05	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	7.92e-06	1.92e-05	CbGpPWpGaD
Crizotinib—JAK3—Signaling Pathways—TP53—chronic obstructive pulmonary disease	7.91e-06	1.92e-05	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	7.83e-06	1.9e-05	CbGpPWpGaD
Crizotinib—PTK2—Immune System—IL6—chronic obstructive pulmonary disease	7.83e-06	1.9e-05	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—SERPINE1—chronic obstructive pulmonary disease	7.83e-06	1.9e-05	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—CYP1A1—chronic obstructive pulmonary disease	7.82e-06	1.9e-05	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—HTR2A—chronic obstructive pulmonary disease	7.78e-06	1.89e-05	CbGpPWpGaD
Crizotinib—TYK2—Signaling by GPCR—IL6—chronic obstructive pulmonary disease	7.78e-06	1.89e-05	CbGpPWpGaD
Crizotinib—SRC—Disease—NOS3—chronic obstructive pulmonary disease	7.74e-06	1.88e-05	CbGpPWpGaD
Crizotinib—YES1—Immune System—IL6—chronic obstructive pulmonary disease	7.72e-06	1.87e-05	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	7.68e-06	1.86e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling by GPCR—EGFR—chronic obstructive pulmonary disease	7.67e-06	1.86e-05	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	7.62e-06	1.85e-05	CbGpPWpGaD
Crizotinib—LYN—Immune System—EGFR—chronic obstructive pulmonary disease	7.49e-06	1.82e-05	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	7.47e-06	1.81e-05	CbGpPWpGaD
Crizotinib—ABL1—Immune System—EGFR—chronic obstructive pulmonary disease	7.46e-06	1.81e-05	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	7.4e-06	1.8e-05	CbGpPWpGaD
Crizotinib—IRAK1—Immune System—IL6—chronic obstructive pulmonary disease	7.32e-06	1.78e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—SERPINE1—chronic obstructive pulmonary disease	7.32e-06	1.78e-05	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	7.32e-06	1.78e-05	CbGpPWpGaD
Crizotinib—JAK3—Signaling Pathways—IL6—chronic obstructive pulmonary disease	7.24e-06	1.76e-05	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—LEP—chronic obstructive pulmonary disease	7.24e-06	1.76e-05	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	7.22e-06	1.75e-05	CbGpPWpGaD
Crizotinib—SRC—Innate Immune System—IL6—chronic obstructive pulmonary disease	7.17e-06	1.74e-05	CbGpPWpGaD
Crizotinib—SRC—Immune System—IL1B—chronic obstructive pulmonary disease	7.14e-06	1.73e-05	CbGpPWpGaD
Crizotinib—TYK2—Immune System—IL6—chronic obstructive pulmonary disease	7.11e-06	1.73e-05	CbGpPWpGaD
Crizotinib—RIPK2—Signaling Pathways—TP53—chronic obstructive pulmonary disease	7.05e-06	1.71e-05	CbGpPWpGaD
Crizotinib—JAK2—Immune System—EGFR—chronic obstructive pulmonary disease	7.01e-06	1.7e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	6.99e-06	1.7e-05	CbGpPWpGaD
Crizotinib—PTK2B—Signaling Pathways—TP53—chronic obstructive pulmonary disease	6.95e-06	1.69e-05	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	6.85e-06	1.66e-05	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—GSTP1—chronic obstructive pulmonary disease	6.77e-06	1.64e-05	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	6.72e-06	1.63e-05	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—HMOX1—chronic obstructive pulmonary disease	6.68e-06	1.62e-05	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—TP53—chronic obstructive pulmonary disease	6.65e-06	1.61e-05	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	6.65e-06	1.61e-05	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	6.63e-06	1.61e-05	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	6.63e-06	1.61e-05	CbGpPWpGaD
Crizotinib—JAK2—Disease—TGFB1—chronic obstructive pulmonary disease	6.6e-06	1.6e-05	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	6.59e-06	1.6e-05	CbGpPWpGaD
Crizotinib—TYK2—Disease—IL6—chronic obstructive pulmonary disease	6.56e-06	1.59e-05	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	6.5e-06	1.58e-05	CbGpPWpGaD
Crizotinib—JAK2—Disease—EGFR—chronic obstructive pulmonary disease	6.47e-06	1.57e-05	CbGpPWpGaD
Crizotinib—RIPK2—Signaling Pathways—IL6—chronic obstructive pulmonary disease	6.45e-06	1.57e-05	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—TP53—chronic obstructive pulmonary disease	6.45e-06	1.56e-05	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—SERPINE1—chronic obstructive pulmonary disease	6.41e-06	1.56e-05	CbGpPWpGaD
Crizotinib—PTK2B—Signaling Pathways—IL6—chronic obstructive pulmonary disease	6.36e-06	1.54e-05	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	6.28e-06	1.52e-05	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—GSTM1—chronic obstructive pulmonary disease	6.22e-06	1.51e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	6.2e-06	1.51e-05	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	6.16e-06	1.5e-05	CbGpPWpGaD
Crizotinib—LCK—Immune System—EGFR—chronic obstructive pulmonary disease	6.14e-06	1.49e-05	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	6.12e-06	1.49e-05	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	6.1e-06	1.48e-05	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—IL6—chronic obstructive pulmonary disease	6.09e-06	1.48e-05	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—GSTT1—chronic obstructive pulmonary disease	6.02e-06	1.46e-05	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	5.99e-06	1.45e-05	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	5.98e-06	1.45e-05	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—GCLC—chronic obstructive pulmonary disease	5.95e-06	1.44e-05	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—IL6—chronic obstructive pulmonary disease	5.9e-06	1.43e-05	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—CYP1A1—chronic obstructive pulmonary disease	5.9e-06	1.43e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling by GPCR—IL6—chronic obstructive pulmonary disease	5.9e-06	1.43e-05	CbGpPWpGaD
Crizotinib—LCK—Disease—TGFB1—chronic obstructive pulmonary disease	5.78e-06	1.4e-05	CbGpPWpGaD
Crizotinib—LYN—Immune System—IL6—chronic obstructive pulmonary disease	5.76e-06	1.4e-05	CbGpPWpGaD
Crizotinib—ABL1—Immune System—IL6—chronic obstructive pulmonary disease	5.73e-06	1.39e-05	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—SERPINE1—chronic obstructive pulmonary disease	5.68e-06	1.38e-05	CbGpPWpGaD
Crizotinib—LCK—Disease—EGFR—chronic obstructive pulmonary disease	5.67e-06	1.38e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	5.61e-06	1.36e-05	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—TP53—chronic obstructive pulmonary disease	5.53e-06	1.34e-05	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—TP53—chronic obstructive pulmonary disease	5.45e-06	1.32e-05	CbGpPWpGaD
Crizotinib—SRC—Immune System—EGFR—chronic obstructive pulmonary disease	5.44e-06	1.32e-05	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	5.43e-06	1.32e-05	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—CTGF—chronic obstructive pulmonary disease	5.43e-06	1.32e-05	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	5.42e-06	1.32e-05	CbGpPWpGaD
Crizotinib—JAK2—Immune System—IL6—chronic obstructive pulmonary disease	5.39e-06	1.31e-05	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	5.38e-06	1.31e-05	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—ALB—chronic obstructive pulmonary disease	5.31e-06	1.29e-05	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—TP53—chronic obstructive pulmonary disease	5.17e-06	1.26e-05	CbGpPWpGaD
Crizotinib—SRC—Disease—TGFB1—chronic obstructive pulmonary disease	5.12e-06	1.24e-05	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—NOS3—chronic obstructive pulmonary disease	5.08e-06	1.23e-05	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—IL6—chronic obstructive pulmonary disease	5.06e-06	1.23e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	5.04e-06	1.22e-05	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—TP53—chronic obstructive pulmonary disease	5.02e-06	1.22e-05	CbGpPWpGaD
Crizotinib—SRC—Disease—EGFR—chronic obstructive pulmonary disease	5.02e-06	1.22e-05	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—CYP1A2—chronic obstructive pulmonary disease	5e-06	1.21e-05	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—IL6—chronic obstructive pulmonary disease	4.99e-06	1.21e-05	CbGpPWpGaD
Crizotinib—JAK2—Disease—IL6—chronic obstructive pulmonary disease	4.98e-06	1.21e-05	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	4.94e-06	1.2e-05	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	4.91e-06	1.19e-05	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	4.84e-06	1.18e-05	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	4.81e-06	1.17e-05	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—IL6—chronic obstructive pulmonary disease	4.74e-06	1.15e-05	CbGpPWpGaD
Crizotinib—LCK—Immune System—IL6—chronic obstructive pulmonary disease	4.72e-06	1.15e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	4.62e-06	1.12e-05	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—IL6—chronic obstructive pulmonary disease	4.6e-06	1.12e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	4.53e-06	1.1e-05	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	4.41e-06	1.07e-05	CbGpPWpGaD
Crizotinib—LCK—Disease—IL6—chronic obstructive pulmonary disease	4.36e-06	1.06e-05	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	4.35e-06	1.06e-05	CbGpPWpGaD
Crizotinib—SRC—Immune System—IL6—chronic obstructive pulmonary disease	4.18e-06	1.01e-05	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—GSTP1—chronic obstructive pulmonary disease	4.17e-06	1.01e-05	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—HMOX1—chronic obstructive pulmonary disease	4.11e-06	9.99e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—TP53—chronic obstructive pulmonary disease	4.07e-06	9.87e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	4.05e-06	9.83e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—ALB—chronic obstructive pulmonary disease	4.01e-06	9.73e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	3.97e-06	9.63e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	3.91e-06	9.48e-06	CbGpPWpGaD
Crizotinib—SRC—Disease—IL6—chronic obstructive pulmonary disease	3.86e-06	9.36e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—NOS3—chronic obstructive pulmonary disease	3.84e-06	9.31e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—GSTM1—chronic obstructive pulmonary disease	3.83e-06	9.3e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—TP53—chronic obstructive pulmonary disease	3.81e-06	9.24e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—IL6—chronic obstructive pulmonary disease	3.72e-06	9.03e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—CYP1A1—chronic obstructive pulmonary disease	3.63e-06	8.82e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	3.58e-06	8.7e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	3.52e-06	8.53e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—IL6—chronic obstructive pulmonary disease	3.48e-06	8.45e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—TP53—chronic obstructive pulmonary disease	3.33e-06	8.09e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—IL6—chronic obstructive pulmonary disease	3.05e-06	7.4e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—TP53—chronic obstructive pulmonary disease	2.95e-06	7.16e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—IL6—chronic obstructive pulmonary disease	2.7e-06	6.56e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—ALB—chronic obstructive pulmonary disease	2.47e-06	6e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—NOS3—chronic obstructive pulmonary disease	2.36e-06	5.73e-06	CbGpPWpGaD
